Intramuscular 17-hydroxyprogesterone caproate to prevent preterm birth among HIV-infected women in Zambia: study protocol of the IPOP randomized trial by Price, Joan T. et al.
STUDY PROTOCOL Open Access
Intramuscular 17-hydroxyprogesterone
caproate to prevent preterm birth among
HIV-infected women in Zambia: study
protocol of the IPOP randomized trial
Joan T. Price1,2* , Bellington Vwalika1,2, Bethany L. Freeman1, Stephen R. Cole3, Helen B. Mulenga4,
Jennifer Winston1, Felistas M. Mbewe5, Elwyn Chomba6, Lynne M. Mofenson7, Dwight J. Rouse8,
Robert L. Goldenberg9 and Jeffrey S. A. Stringer1
Abstract
Background: Each year, an estimated 15 million babies are born preterm, a global burden borne disproportionately
by families in lower-income countries. Maternal HIV infection increases a woman’s risk of delivering prematurely,
and antiretroviral therapy (ART) may compound this risk. While prenatal progesterone prophylaxis prevents preterm
birth among some high-risk women, it is unknown whether HIV-infected women could benefit from this therapy.
We are studying the efficacy of progesterone supplementation to reduce the risk of preterm birth among pregnant
women with HIV in Lusaka, Zambia.
Methods: The Improving Pregnancy Outcomes with Progesterone (IPOP) study is a Phase III double-masked,
placebo-controlled, randomized trial of intramuscular 17-alpha hydroxprogesterone caproate (17P) to prevent
preterm birth in HIV-infected women. A total of 800 women will be recruited prior to 24 weeks of gestation and
randomly allocated to 17P or placebo administered by weekly intramuscular injection. The primary outcome will be
a composite of live birth prior to 37 completed gestational weeks or stillbirth at any gestational age. Secondary
outcomes will include very preterm birth (< 34 weeks), extreme preterm birth (< 28 weeks), small for gestational age
(<10th centile), low birth weight (< 2500 g), and neonatal outcomes. In secondary analysis, we will assess whether
specific HIV-related covariates, including the timing of maternal ART initiation relative to conception, is associated
with progesterone’s prophylactic efficacy, if any.
Discussion: We hypothesize that weekly prenatal 17P will reduce the risk of HIV-related preterm birth. An
inexpensive intervention to prevent preterm birth among pregnant women with HIV could have substantial global
public health impact.
Trial registration: NCT03297216; September 29, 2017.
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Background
Each year worldwide nearly 15 million babies are born
prior to 37 weeks of gestation, of whom 1 million die as
a consequence of prematurity [1]. The burden of pre-
term birth (PTB) and its associated mortality and
long-term disability is disproportionately borne by the
world’s poorest families. More than 60% of global pre-
term deliveries occur in South Asia and sub-Saharan Af-
rica, where resources to care for premature newborns
are scarce and case fatality is high [2]. The geographic
disparity in rates of prematurity may in part reflect the
distribution of maternal HIV, which increases the risk of
PTB [3]. Of 1.5 million women living with HIV who be-
come pregnant each year, the overwhelming majority
reside in either sub-Saharan Africa (87%) or South Asia
(5%) [4]. While expanding coverage of antiretroviral
therapy (ART) among pregnant women living with HIV
has drastically reduced the incidence of mother-to-child
transmission, maternal ART exposure does not appear
to ameliorate the increased risk of PTB in HIV-infected
pregnant women [5–10]. Additionally, neonatal mortal-
ity remains elevated in HIV-infected pregnant women
on ART compared to HIV-uninfected women; in a study
comparing women on efavirenz or dolutegravir-based
ART, neonatal mortality was 2.3% among HIV-infected
compared to 1.4% among HIV-uninfected women [9]. A
considerable proportion of this neonatal mortality ap-
pears to be secondary to PTB [6].
Prenatal progesterone reduces the risk of preterm de-
livery in women who have had a prior spontaneous PTB
and in those with sonographic evidence of cervical
shortening in the mid-trimester. It is standard of care in
the United States for these indications [11]. A 2013
Cochrane meta-analysis of progesterone to prevent PTB
among women reporting a prior PTB aggregated data
from 10 randomized trials studying prenatal prophylaxis
by the intramuscular (IM, n = 4 studies), vaginal (n = 5
studies), or oral (n = 1 study) route and estimated the
risk ratio of birth prior to 37 weeks among women re-
ceiving active drug to be 0.55 (95% CI: 0.42, 0.74) [12].
We seek to determine whether 17-hydroxyprogesterone
caproate (17P) will reduce the risk of PTB among
HIV-infected pregnant women receiving ART. Here we
present the study protocol for a randomized trial designed
to answer this question.
Methods
Study design
The Improving Pregnancy Outcomes with Progesterone
(IPOP) trial is a double-masked, placebo-controlled, ran-
domized trial of 17P to prevent PTB among HIV-infected
women in Zambia. It is registered with clinicaltrials.gov
under identifier: NCT03297216. Participants are randomly
assigned to weekly intramuscular administration of either
17P or placebo manufactured to be indistinguishable
started between 16 and 24weeks gestational age. The
study’s primary outcome is a composite measure of deliv-
ery prior to 37 weeks or stillbirth at any gestational age.
IPOP is being conducted in the antenatal clinics of the
Kamwala District Health Centre (KDHC) and Women
and Newborn Hospital of the University Teaching Hos-
pital (WNH-UTH) in Lusaka. We also recruit participants
from other public sector facilities in Lusaka. The IPOP
trial has been designed following the Consolidated Stan-
dards of Reporting Trials (CONSORT 2010) Statement
and the Standards for Protocol Items: Recommendations
for Interventional Trials (SPIRIT 2013) (Fig. 1) [13, 14].
Study participants
Women meeting the following inclusion criteria are eli-
gible to participate in the IPOP study: (1) 18 years of age
Fig. 1 IPOP study participant flow diagram
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or older; (2) viable intrauterine singleton pregnancy con-
firmed by ultrasound; (3) less than 24 0/7 weeks of gesta-
tion; (4) antibody-confirmed HIV-1 infection; (5)
currently receiving ART or intending to commence ART
in pregnancy; (6) ability and willingness to provide writ-
ten informed consent; (7) intent to remain in current
geographical area of residence for the duration of study;
and (8) willing to adhere to weekly study visit schedule.
We exclude from participation any woman with the add-
itional exclusion criteria: (1) confirmed prior spontan-
eous preterm birth; (2) multiple gestation; (3) known
uterine anomaly; (4) planned or in situ cervical cerclage;
(5) major fetal anomaly detected on screening ultra-
sound; (6) indication for planned delivery prior to 37
weeks (e.g. prior classical cesarean); (7) evidence of
threatened abortion, preterm labor, or ruptured mem-
branes at time of enrollment; (8) known allergy or med-
ical comorbidity listed as a contraindication to 17P in
the prescribing information; (9) prior participation in the
trial; and (10) any other condition (social or medical)
which, in the opinion of the study staff, would make trial
participation unsafe or complicate data interpretation.
Current Zambia treatment guidelines recommend ART
initiation for all individuals living with HIV, including
pregnant and breastfeeding women [15]. The current ART
regimen for first-line therapy for pregnant women living
with HIV in Zambia is combination tenofovir disoproxil
fumarate, lamivudine and efavirenz, with second-line ther-
apy being combination zidovudine, lamivudine and a pro-
tease inhibitor, lopinavir-ritonavir or atazanavir-ritonavir;
most pregnant women are receiving first-line ART.
Intervention
Trial participants are randomly allocated to one of two
treatment groups in a 1:1 ratio. The first randomization
group (17P) receives weekly 1 mL injections of 250 mg
17-hydroxyprogesterone caproate while the other group
(control) receives placebo manufactured to be indistin-
guishable, also by injection.
Study product (both active drug and placebo) is pro-
duced by AMAG Pharmaceuticals of Waltham, MA,
USA, under the brand name of Makena®. Packaged and
labeled product is shipped to each study site and dis-
pensed to the administering nurse by an on-site pharma-
cist or pharmacy technician. Pharmacy staff have no
direct contact with participants or potential participants,
and are the only staff in Zambia not masked to treat-
ment allocation. Participants begin weekly administra-
tion of study product from the day of randomization
(between 16 0/7 and 23
6/7 gestational weeks, inclusive)
until 36 6/7 gestational weeks, stillbirth or delivery,
whichever is sooner.
If an adverse drug reaction is identified in any partici-
pant receiving injections of study product, staff will
consult with investigators to determine whether the re-
action requires temporary or permanent discontinuation
of study product based on the severity of the event and
whether or not the event resolves. Study product will be
immediately and permanently discontinued for any par-
ticipant who has an anaphylactic reaction. The investiga-
tor will decide whether to un-blind the treatment group
to guide treatment and future care for the participant. In
general, adverse drug reactions will typically not require
un-blinding of study group and will not necessarily indi-
cate that a participant is receiving the active product
since components in the placebo base may also result in
adverse reactions.
Objectives
The primary objective of IPOP is to evaluate – among
HIV-infected pregnant women receiving ART – whether
17P will reduce the risk of the composite outcome (live
birth prior to 37 weeks of gestation or stillbirth at any
gestational age) relative to placebo. Secondary objectives
include: (1) to assess, through a subgroup analysis,
whether 17P will reduce the risk of the primary outcome
among women either (a) newly initiating ART or (b)
continuing ART that was started prior to conception; (2)
to assess the effect of timing of ART initiation on risk of
the composite primary outcome and its components by
comparing women newly starting ART to those who ini-
tiate ART prior to conception (a non-randomized com-
parison); and (3) to assess the extent to which exclusion
of non-inflammatory PTB phenotypes from our outcome
definition modifies the efficacy of 17P to prevent the
composite primary outcome and/or any association be-
tween timing of ART initiation and the composite pri-
mary outcome. Finally, our tertiary objective is to
investigate the underlying biology of PTB and other ad-
verse pregnancy outcomes with particular attention to
systemic (peripheral blood) inflammation and immune
activation, local (vaginal) inflammation, and alterations
of the vaginal microbiota.
Study procedures
Our recruitment activities include community
sensitization in the catchment area of the recruitment
clinics to educate community members about the trial
and encourage early presentation for antenatal care. In
addition, study staff conduct health talks at the recruit-
ment clinics focusing on the importance of early and
complete antenatal care, possible prevention of preterm
delivery, and study inclusion and exclusion criteria.
Study staff identify potential participants attending
antenatal care prior to 24 estimated gestational weeks
(Table 1). An ultrasound is conducted to confirm poten-
tial study eligibility and, among women between 16 and
24 weeks of gestation, cervical length by transvaginal
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ultrasound [16]. Those who meet preliminary eligibility
by ultrasound and who agree to participation undergo a
detailed informed consent process in English, Bemba, or
Nyanja, depending on their language preference. After
consent, study staff verify antenatal and HIV history data
through a baseline questionnaire and review of partici-
pants’ available medical records, perform a physical
exam, and complete point of care testing for antenatal
care and to confirm participants’ HIV status.
Participants then undergo randomization into one of
two treatment groups and start study drug as early as
possible within the window of 16 and 24 weeks of gesta-
tion. Eligible women who choose to participate at the
screening visit are given a subsequent appointment for
randomization no earlier than the following business day
to encourage careful consideration of the risks and bene-
fits of study participation. On the day of randomization,
following final confirmation of eligibility, participants
are assigned with equal probability into one of two study
groups. Our randomization scheme stratifies participants
by timing of ART initiation (during current pregnancy /
pre-pregnancy). A statistician from the UNC Center for
Table 1 IPOP study schedule of evaluations
Visit Number 0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0
Gestational Age (weeks) < 24 16–23 24 28 32 36 Deliveryc 42 days
Administrative/regulatory procedures
Informed consent ●
Confirmation of eligibility ●
Collection/review of locator info ● ● ● ● ● ● ● ●
Randomization ●
Clinical/behavioral procedures
Ultrasounda ● ● ●
Obstetrical history ●
Medical history and clinical exama ● ● ● ● ● ●
Concomitant medication assessment ● ● ● ● ● ●
Demographic history ●
Behavioral and nutritional assessment ● ●
Maternal depression screen ● ●
Infant clinical assessment ● ●
Study product procedures
17P Adherence counselingb ● ● ● ● ●
Study drug injectionsb ● ● ● ● ●
Side effects assessmentb ● ● ● ●
Laboratory procedures
Maternal rapid HIV a ●
Maternal pregnancy testa ●
Maternal rapid syphilis a ●
Maternal candida, gram staina ●
Maternal hemoglobin (HemoCue)a ● ●
Maternal urinalysisa ● ●
Maternal viral load and T cell assays ● ● ●
Placenta, membranes, cord blood storage ●
Infant HIV DNA PCRa ●
Vaginal-rectal swab storage ● ● ● ●
Blood storage ● ● ● ●
Urine storage ● ● ● ●
aPerformed as standard antenatal care
bOccurs weekly through week 36, or until delivery, whichever occurs first
cAll procedures may not be completed for women who deliver off-hours or in a location without staff coverage
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AIDS Research Biostatistics Core not otherwise associated
with the study created the scheme using random per-
muted blocks. At the time of randomization, a research
nurse confirms eligibility in a web-based randomization
program. Using the same web-based tool, the pharmacist
then performs the randomization procedure and prepares
the 1mL injection of the assigned study treatment, which
the research nurse administers to the participant. All
randomization documentation is stored securely.
Once IPOP participants start study drug, they are seen
weekly (Fig. 2). At each injection visit, study staff evalu-
ate participants for side effects of IM progesterone,
which are expected to be rare and generally mild, but in-
clude injection-site reactions, headache, breast tender-
ness, nausea, and cough. In addition, the study provides
routine antenatal care to all participants following
Zambian national guidelines at: 24, 32, and 36 gesta-
tional weeks.
At the 24- and 28-week study visits, blood, urine, and
vaginal swabs are collected. At the time of delivery or
shortly thereafter, blood, urine, and vaginorectal swabs
are collected (Table 1). At delivery, study nurses collect
samples of the placenta, umbilical cord, and cord blood.
Also at delivery, study nurses obtain detailed informa-
tion about the participant and her infant’s clinical course
by patient self-report, review of medical records, or by
direct assessment. We assign a clinical phenotype [17]
for all PTB and stillbirth outcomes as soon as possible
following delivery. Finally, we conduct a routine 42-day
postnatal visit, which includes clinical assessment of
both mother and infant, and testing for infant HIV
infection.
Laboratory procedures
Study staff obtain all samples from trial participants ac-
cording to standard operating procedures. All samples
are processed according to the assay manufacturers’
specifications. Some specimens collected from patients
in this protocol are analyzed immediately per standard
antenatal care guidelines. Others are stored temporarily
for later study-related analysis to investigate biological
mechanisms contributing to preterm birth and other ad-
verse birth outcomes.
Study monitoring
An external monitor will be contracted to oversee the
progress of the clinical trial and to ensure that it is con-
ducted, recorded, and reported in accordance with the
protocol, standard operating procedures, International
Conference on Harmonization / Good Clinical Practices,
the Zambian National Health Research Act, and U.S. 45
CFR 46 requirements. The monitor will verify that the
data reported is valid, accurate, and complete through
review of case report forms, medical records, and source
documentation. The monitor will make site visits each
quarter through the end of the study and will provide
verbal and written feedback to the study site for ongoing
quality control and improvement.
We will constitute a Data Safety and Monitoring
Board (DSMB) to periodically monitor trial performance
and safety. The group will comprise senior investigators
with statistical, methodological, and topical expertise
who are not otherwise involved with the study. Their
first charge will be to review the study protocol and cre-
ate a monitoring schedule and stopping guidelines,
based on expected event rates. Other specific duties will
include: (1) periodic assessments of recruitment, accrual,
retention, and data quality; (2) considering new external
data as they come available, including scientific or thera-
peutic developments that may have an impact on partici-
pant safety or the ethics of the trial; (3) evaluation of
scheduled interim analysis. Mortality outcomes will be
reviewed by the DSMB during routine meetings. The
DSMB will have authority to enjoin enrolment or stop
the study altogether for reasons of patient safety. If an
interim analysis were to show unequivocal benefit before
follow-up were complete, we would support stopping
the study and reprogramming remaining resources to
make the intervention available to all participants.
Primary outcome
Our primary outcome is a composite of live birth occur-
ring before 37 gestational weeks or stillbirth at any ges-
tational age. Secondary outcomes are: delivery prior to
34 weeks of gestation and prior to 28 weeks of gestation;
birth weight < 10th percentile for gestational age; birth
weight < 3rd percentile for gestational age;
mother-to-child HIV transmission by 6 weeks postpar-
tum; cumulative incidences of the competing risks of
stillbirth and PTB; neonatal and perinatal mortality
rates; infant APGAR scores. Our tertiary outcomes are:
birth weight < 2500 g and < 1500 g; measures of maternal
inflammation and/or immune activation; alterations of
the vaginal microbiome; measures of infant morbidity
(e.g., intensive care unit admission, supplemental oxygen
requirement, need for assisted ventilation); and serious
adverse events and events resulting in study product
discontinuation.
Sample size
We estimated the baseline risk of the composite out-
come (p1) as 24%, based on estimates of preterm birth
(21%) plus stillbirth (3%) among HIV-infected women in
Zambia from our own local data [18, 19] and from mod-
eled data [2]. We hypothesize that 17P will reduce the
proportion of HIV-infected women experiencing the
composite endpoint by 38% (from 24 to 15%) [12]. A
trial with 325 patients per group would have 80% power
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Fig. 2 IPOP study trial schema
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to detect this effect size (based on a 2-sided Fisher’s
exact test at the 0.05 significance level). To allow for up
to 15% follow-up loss and to account for uncertainty in
our estimates of baseline event probability (p1) and rela-
tive efficacy of the intervention, we set target enrollment
at 400 women per randomization group in the trial.
Statistical analysis plan
We will assign an estimated delivery date (EDD) by
ultrasound biometry measurements collected at time of
enrollment, using the INTERGROWTH 21st standards
[20, 21]. We do not consider the participants’ reported
last menstrual period in our gestational age calculations,
as this has been shown in our setting to introduce bias
[22]. Randomized women who deliver (1) a live infant 21
or more days before their assigned EDD or (2) a stillborn
infant at any gestational age will be categorized as hav-
ing met the primary outcome.
The primary analysis will employ the intent-to-treat
principle, wherein each mother-infant pair will be analyzed
according to randomization assignment regardless of
whether the mother complied with study procedures. The
primary comparison between the two trial groups will be
based on the estimated risk ratio of the primary outcome.
The estimated risk of the primary outcome will be com-
puted in each group using the Kaplan-Meier method to ad-
just for loss-to-follow-up, where mother-infant pairs who
drop out of the trial prior to the primary outcome or
live-birth of full-term infant will be right censored at their
last study visit. A Z-statistic will be constructed by taking
the difference in the estimated log risks divided by the cor-
responding estimated standard error (using the Greenwood
estimator). As a sensitivity analysis, a Cox proportional haz-
ards model with treatment assignment as the sole covariate
will be fit to estimate the hazard of meeting the primary
endpoint between randomization groups; the estimated
hazard ratio is anticipated to be similar to the estimated risk
ratio given that the primary outcome is relatively rare.
We plan to undertake a pre-specified subgroup ana-
lysis for this trial. This subgroup analysis will assess
whether the effect of 17P differs within levels of the
stratification factor. Effect modification will be assessed
by fitting Cox proportional hazards models that include
randomization group, the stratification factor, and a
product term as covariates. A likelihood ratio test of the
product term coefficient will be used to assess possible
effect modification. If the effect modification tests are
significant, hazard ratios will be estimated separately
within levels of the factor (e.g., hazard ratios of 17P ver-
sus placebo for (i) mothers on pre-pregnancy ART and
(ii) mothers initiating ART in pregnancy).
To assess the efficacy of 17P, a per-protocol analysis of
the primary outcome will also be conducted that censors
participants who fail to comply with their randomization
assignment (defined here as missing two injections of
study product in a row), and then reweights the data to
account for possible informative censoring by noncompli-
ance using inverse-probability (IP) weights [23]. We have
previously used this and related methods to construct a
consistent estimator of the per-protocol effect under the
assumption that we have measured and correctly-adjusted
for the common causes of noncompliance and the out-
come [24–26]. The set of measured possible common
causes includes demographic, medical, and obstetrical fac-
tors. We will construct IP weights using pooled logistic re-
gression (pooling over time), with continuous variables fit
using flexible restricted splines. We will explore the sensi-
tivity to IP weight estimation [27].
Ethical considerations
Participation in this trial is voluntary. All participants
undergo a comprehensive written informed consent
process prior to study enrollment. Clinical study proce-
dures are conducted according to local standards of rou-
tine care. All staff with direct participant contact receive
training on protecting human research participants [28]
before performing any study procedures and routinely
thereafter. Key staff also undergo Good Clinical Practices
training [29] no less frequently than every 3 years. The
University of Zambia Biomedical Research Ethics Com-
mittee and the University of North Carolina at Chapel
Hill Institutional Review Board each granted approval of
the IPOP trial protocol before enrollment commenced.
Investigators make every reasonable effort to minimize
risks to participants. We expect that participants will be
exposed to minimal risk in this trial. Side effects and ser-
ious adverse events associated with 17P administration
have been studied extensively and are rare [30]. Women
with one or more contraindication to 17P that appear in
the Makena® package insert [31] are excluded from the
trial. Physical risks of IPOP study participation also in-
clude the risks associated with venipuncture, which are
infrequent and minimized with the use of proper tech-
nique. Collection of vaginal and rectal samples may also
be associated with some discomfort or mild bleeding.
Participation in clinical research includes possible
breach of confidentiality as well as discomfort with per-
sonal medical and socio-behavioral questions. Although
investigators make every effort to protect participant
privacy and confidentiality to reduce these risks (e.g., by
conducting consent procedures in a private setting and
do not include participant names on case report forms),
it is possible that participant involvement in the study
could become known to others, and that social harms
may result (e.g., participants could become known as
HIV-infected).
At each study visit, study staff assess participants for
occurrence of social harms and adverse events. The
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severity of any study-related adverse events is graded
based on the National Institute of Health’s Division of
AIDS Table for Grading the Severity of Adult and
Pediatric Adverse Events [32]. Study staff report adverse
events or social harms that are related to the study drug
and/or study participation according to requirements by
each individual regulatory authority.
To maintain participant confidentiality, all laboratory
specimens, reports, study data, and administrative forms
are identified by a coded number only. All databases are
secured with password-protected access systems, and
computer entries are identified by coded number only.
Forms, lists, logbooks, appointment books, and any
other listings or data forms that link participant identifi-
cation numbers to other identifying information are
stored in a separate, locked cabinet. All statistical ana-
lyses will use data identified only by the coded study
number. Clinical information with individual identifiers
will not be released without the written permission of
the participant.
Participants who receive 17P in the IPOP trial may
benefit from a reduced risk of delivering preterm if the
intervention is indeed effective, but it is also possible
that there will be no effect. Participants in both study
groups may benefit from added health education and
counseling, comprehensive antenatal care, and close
follow-up. Findings from this study could shape health
policy and clinical care, or inform future research in the
prevention of HIV-related PTB. We intend to make all
learning from this trial widely and quickly available by
publishing in open access journals to facilitate informed
decision-making by key stakeholders engaged in PTB
prevention worldwide.
Discussion
The global epidemics of preterm birth and HIV converge
in sub-Saharan Africa, where the skilled providers and
resources needed to care for preterm neonates are
scarce. Antiretroviral therapy for the prevention of
mother-to-child HIV transmission has led to encour-
aging reductions in new cases of pediatric HIV, but des-
pite preventing transmission this treatment does not
appear to reduce the elevated risk of PTB and neonatal
morbidity/mortality compared to HIV-uninfected preg-
nant women; in a study in Botswana 23% of women liv-
ing with HIV on ART experience PTB compared to 15%
of uninfected women [10]. In resource-limited settings
where HIV complicates a considerable proportion of
pregnancies, strategies to ameliorate PTB risk in women
using ART could result in a substantial public health
impact.
With this Phase III double-masked, placebo-controlled,
randomized clinical trial, we aim to discover whether 17P
will prevent PTB and stillbirth among HIV-infected
women receiving ART in pregnancy. We will also, through
planned sub-group analysis, gain insight into whether the
effect of 17P varies between women initiating antiretro-
viral therapy prior pregnancy versus those newly starting
treatment in pregnancy. Although pilot studies of vaginal
progesterone to prevent PTB among HIV-infected women
are ongoing [33, 34], the IPOP Study represents the first
full-scale efficacy trial of antenatal progesterone in this
population. If efficacious in this high-risk group, 17P has
the potential to prevent hundreds of thousands of preterm
births per year worldwide.
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